The Chinese covid-19 vaccine candidate – BBIBP-corvi – which is likely to completely inactivate the SARS-cov-2 virus, is safe and receives an antibody response, according to a study published in The Lancet.
Similar results were reported in a previous clinical trial for a different vaccine based on the inactivated whole SARS-Covi-2 virus, but in that study the vaccine was only given to people under 60 years of age.
A recent study, reported in the Lancet Journal of Infectious Diseases, included participants aged 18 to 80, and found that the antibody response was induced in all recipients.
Participants over the age of 60 were slower to respond, compared to 28 days of participants aged 18-25, 42 days before antibodies were found in all recipients.
“Protecting the elderly is the main goal of the successful Covid-19 vaccine because this age group is at higher risk of developing the disease,” said Xiaming Yang, study author at the Beijing Institute of Biological Products Co., Ltd. of China. Said study author Xiaming Yang.
However, vaccines in this group are sometimes less effective, as the immune system weakens with age.
Yang added, “It is therefore encouraging to see that BBIBP-Corvi induces antibody responses in people over the age of 60, and we believe this justifies further investigation.”
The BBIBP-Corvi vaccine used in the study reported here is based on a sample of the virus that was isolated from a patient in China.
Stocks of the virus were grown in the lab using cell lines and then inactivated using a chemical called beta-proprionectone.
BBIBP-Corvi contains another ingredient, a killer virus mixed with aluminum hydroxide, which is called auxiliary because it is known to stimulate the immune response.
The first phase of the study was created to find the best safe dose for BBIBP-CorV.
It included 96 healthy volunteers between the ages of 18 and 59 and another group of 96 participants between the ages of 60 and 80.
Within each group, the vaccine was tested at three different dose levels, with two vaccines being given on day zero and 28th.
A fourth group (24 participants from each age group) within each age group was given two doses of the placebo vaccine. In total, in the first phase of the study, 144 participants were vaccinated and 48 received placebo.
The second phase of the study was designed to identify the maximum time schedule for vaccination.
Participants were asked to report any adverse events for the first seven days after each vaccination and this was verified by the research team.
“No serious adverse events were reported within 28 days of the final vaccination. Laboratory tests in any of the groups showed no clinically significant changes in organ function,” the authors wrote.
Latest information on OTT / Streaming Content, Home Delivered!
.
